SCHEMBL4903233

SCHEMBL4903233

COc1ccc(-c2ccnc(Nc3cccc(Nc4nccc(-c5ccc(OC)c(OC)c5)n4)c3)n2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.65
FLT3 P36888 2/20 0.65
PIK3CG P48736 7/20 0.65
PIK3CA P42336 6/20 0.65
PIK3CB P42338 5/20 0.65
CDK5 Q00535 3/20 0.61
EGFR P00533 2/20 0.56
CDK2 P24941 2/20 0.56
PTK2B Q14289 1/20 0.56
ABL1 P00519 5/20 0.55
BCR P11274 4/20 0.55
PRKCA P17252 2/20 0.55
PDGFRB P09619 2/20 0.55
PDGFRA P16234 1/20 0.55
LCK P06239 2/20 0.55
PRKD3 O94806 1/20 0.55
PRKCG P05129 1/20 0.55
PRKCB P05771 1/20 0.55
PRKCH P24723 1/20 0.55
PRKCI P41743 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14088787 0.92 JAK2 (0.59) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4901211 0.92 CDK5 (0.75) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL15534241 0.89 CLK1 (0.63) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4903189 0.88 PIK3CG (0.61) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4734534 0.87 ABL1 (0.68) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4903729 0.85 ABL1 (0.79) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL12274677 0.85 ABL1 (0.60) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL12275354 0.85 PIK3CG (0.67) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4903101 0.85 ABL1 (0.59) JAK2FLT3PIK3CGPIK3CAPIK3CB
SCHEMBL4903489 0.85 ABL1 (0.71) JAK2FLT3EGFRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP JAK2 1695/4885FLT3 537/4885PIK3CG 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.